• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Prenatal Antipsychotic Exposure and Risk of ADHD or Autism Spectrum Disorder

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Recent studies have not found a link between prenatal exposure to antipsychotics and childhood neurodevelopmental disorders
  • However, longer follow-up times are required to assess outcomes like attention deficit hyperactivity disorder (ADHD)
  • Wang et al. (JAMA, Internal Medicine, 2021) sought to determine the association between prenatal antipsychotics exposure and the risk of birth and neurodevelopmental problems

METHODS:

  • Population-based cohort study
  • Population
    • Children born between January 2001 and January 2015
    • Exclusion: Pregnancies with prenatal antidepressant/lithium exposure
  • Exposure
    • Gestational exposure to antipsychotics
  • Study design
    • Propensity score (PS) weighting used to account for differences in baseline covariates
    • Sibling matched analysis used to evaluate confounding by indication
  • Minimum follow-up
    • ASD: 3 years
    • ADHD: 6 years
  • Primary outcomes
    • Preterm birth: <37 gestational weeks
    • Small for gestational age (SGA): Birth weight <2 SD below the mean for gestational age
    • First diagnosis of ADHD and autism spectrum disorder (ASD)

RESULTS:

  • 333,749 mother-child pairs for ADHD
    • Mean (SD) maternal age at delivery: 31.46 (5.03) years
  • 411,251 pairs for ASD
    • Mean (SD) maternal age at delivery: 31.56 (5.01) years
  • No difference in ADHD or ASD diagnoses, or SGA between the exposed and non-exposed cohorts
    • ADHD frequency: 3.95%
      • Weighted hazard ratio (wHR) 1.16 (95% CI, 0.83 to 1.61)
    • ASD frequency: 8.24%
      • wHR 1.06 (95% CI, 0.70 to 1.60)
    • Small for gestational age frequency: 1.70%
      • Weighted odds ratio (wOR) 1.36 (95% CI, 0.86 to 2.14)
  • There was a small increased risk of preterm birth
    • wOR 1.40 (95% CI, 1.13 to 1.75)
  • Additional analyses showed no association between gestationally exposed vs past maternal exposure for any outcome
    • ADHD: wHR 0.99 (95% CI, 0.60 to 1.61)
    • ASD: wHR 1.10 (95% CI, 0.58 to 2.08)
    • Small for gestational age: wOR 1.21 (95% CI, 0.66 to 2.20)
    • Preterm birth: wOR 0.93 (95% CI, 0.70 to 1.24)
  • Sibling-matched analyses also revealed no association between antipsychotic exposure and the primary outcomes
    • ADHD: wHR 0.41 (95% CI, 0.04 to 4.93)
    • ASD: wHR 0.90 (95% CI, 0.40 to 2.01)
    • Small for gestational age: wOR 0.86 (95% CI, 0.32 to 2.31)
    • Preterm birth: wOR 1.25 (95% CI, 0.85 to 1.82)

CONCLUSION:

  • There was no link found between prenatal antipsychotic exposure and increased risk of ADHD, ASD, or SGA
  • Small risk for preterm birth disappeared when past maternal exposure was included in the analysis, indicating that maternal psychiatric disorder may be associated with higher risk rather than gestational exposure
  • The authors conclude

This study’s findings do not suggest an association between prenatal exposure to antipsychotics and the risk of ADHD, ASD, preterm birth, and small for gestational age

Given that maternal psychiatric disorders may increase neurodevelopmental disorder risk in children clinicians should inform individual patients about the benefits and potential risks of using antipsychotics during pregnancy

Learn More – Primary Sources:

Association Between Prenatal Exposure to Antipsychotics and Attention-Deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Preterm Birth, and Small for Gestational Age

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Could Smoking During Pregnancy Increase Risk for ADHD in Offspring?
Cesarean Delivery and Risk of Neurodevelopmental Disorders: Is There a Real Link?
Do Antidepressants During Pregnancy Increase Autism Risk?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site